A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer (Q26800823)

8

0 references

Ann M. Henry

6

object named as

Ann Henry

0 references

Alberto Briganti

4

object named as

Alberto Briganti

0 references

author name string

Robert F Wolff

1

0 references

Steve Ryder

2

0 references

Alberto Bossi

3

0 references

Juanita Crook

5

0 references

Jeffrey Karnes

7

0 references

Theo de Reijke

9

0 references

Nelson Stone

10

0 references

Marion Burckhardt

11

0 references

Steven Duffy

12

0 references

Gillian Worthy

full work available at URL

13

0 references

language of work or name

English

0 references

publication date

November 2015

0 references

http://eprints.whiterose.ac.uk/88865/

content deliverer

White Rose Research Online

0 references

published in

European Journal of Cancer

0 references

volume

51

0 references

issue

16

0 references

page(s)

2345-67

0 references

cites work

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

[PREFERE - the German prostatic cancer study: questions and claims surrounding study initiation in January 2013]

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Megavoltage radiation therapy for carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

[Preliminary results for EORTC trial 22911: radical prostatectomy followed by postoperative radiotherapy in prostate cancers with a high risk of progression]

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Quality of life after radical radiotherapy for prostate cancer: longitudinal study from a randomised trial of external beam radiotherapy alone or in combination with high dose rate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

A review of the current epidemiology and treatment options for prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Latest results from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

A progress report on a prospective randomised trial of open and robotic prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Prognostic markers under watchful waiting and radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Survival Following Radiation and Androgen Suppression Therapy for Prostate Cancer in Healthy Older Men: Implications for Screening Recommendations

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Urinary Obstruction in Prostate Cancer Patients From the Dutch Trial (68 Gy vs. 78 Gy): Relationships With Local Dose, Acute Effects, and Baseline Characteristics

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial).

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Acute and Late Toxicity in a Randomized Trial of Conventional Versus Hypofractionated Three-Dimensional Conformal Radiotherapy for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Updated Results and Patterns of Failure in a Randomized Hypofractionation Trial for High-risk Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Dosimetric effect of setup motion and target volume margin reduction in pediatric ependymoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Radical surgery versus radiotherapy for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Hazards of dose escalation in prostate cancer radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Implications of the prostate intervention versus observation trial (PIVOT).

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Quality of life after radical prostatectomy or watchful waiting.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Radical prostatectomy versus watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Radical prostatectomy versus watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Radiotherapy and short-term androgen deprivation for localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Radical prostatectomy versus observation for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Projections of the cost of cancer care in the United States: 2010-2020.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Results from the Scandinavian Prostate Cancer Group Trial Number 4: a randomized controlled trial of radical prostatectomy versus watchful waiting

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinical

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Influence of number of CAG repeats on local control in the RTOG 86-10 protocol

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Ascertaining cause of death among men in the prostate cancer intervention versus observation trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

A randomised trial of robotic and open prostatectomy in men with localised prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Pre-treatment risk stratification of prostate cancer patients: A critical review

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

NCCN clinical practice guidelines in oncology: prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

Developing guidelines for chronic kidney disease: we should include all of the outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJCA.2015.07.019

7 January 2021

10.1016/J.EJCA.2015.07.019

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

10.1016/J.EJCA.2015.07.019

1314994

Altmetric DOI

0 references

CORE ID

141639061

0 references

Dimensions Publication ID

1038881753

0 references

1314994

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference